2024 OPJU International Technology Conference (OTCON) on Smart Computing for Innovation and Advancement in Industry 4.0 | 979-8-3503-7378-3/24/$31.00 ©2024 IEEE | DOI: 10.1109/OTCON60325.2024.10688287

Machine Learning-Driven Blockchain for Enhanced Drug Discovery and Development in Pharmaceutical Research

Asha V,
Department of Computer Applications,New Horizon College of Engineering, Bangalore;
asha.gurudath@gmail.com

Shaik Anjimoon,
Institute of Aeronautical Engineering, Dundigal, Hyderabad;
shaik.anjimoon@iare.ac.in

Meenu Rani Verma,
Assistant Professor, DoCSBS, GyanGanga Institute of Technology and Sciences, Jabalpur, M.P, India,
MeenuraniVerma@ggits.org

Atul Singla,
Lovely Professional University, Phagwara;
atul.singhla31@gmail.com

Irfan Khan,
Lloyd Institute of Engineering & Technology, Knowledge Park II, Greater Noida, Uttar Pradesh 201306;
irfan.khan@lloydcollege.in

Mohammed Ayad Alkhafaji;
College of Technical Engineering, National University of Science and Technology, Dhi Qar, 64001, Iraq.
mohamed_alkhafaji@nust.edu.iq

***Abstract*- Machine learning (ML) and blockchain technologies have made huge steps forward in the pharmacy business by being used in the process of creating and discovering new medicines. Both breakthroughs were made possible by using both tools together. With the help of a blockchain design powered by machine learning, the study's main goal is to come up with a new way to make drug research more effective and efficient. This method makes it possible to make molecules with a wide range of structure features that have the right pharmacological qualities. You can also make these molecules, improve the plans of clinical trials, and guess how drugs will interact with their targets. Technologies like generative adversarial networks, reinforcement learning methods, and deep learning algorithms have made it possible for these things to be used. If blockchain technology is used throughout the whole process of making medicines, it improves global openness, traceability, and data security. This is because it makes sure that managing data is safe. The tests show that the suggested method works better than the others when it comes to the process of finding and developing new drugs. This is better because the creation process is more precise, accurate, and efficient.**

Keywords- Blockchain, Clinical Trials, Deep Learning, Drug Discovery, Generative Adversarial Networks, Machine Learning, Pharmaceutical Research, Reinforcement Learning, Target Prediction, Technology Integration.

I. INTRODUCTION

Recently, the combination of blockchain technology with machine learning (ML) has become a powerful force in many industries, providing ground-breaking answers to difficult problems. Because of this synergy, pharmaceutical research might undergo a revolution as new medicines are discovered and developed more quickly [1]. The numerous intricate facets of creating new medications have long plagued the pharmaceutical industry. It has been difficult to quickly identify promising medication candidates, streamline clinical studies, and comprehend all applicable rules [2]. However, by utilizing machine learning-driven blockchain technology, researchers and other stakeholders may be able to improve the security, effectiveness, and transparency of the pharmaceutical development process [3]. This means that the healthcare sector is poised to enter a golden era of innovation. This article will examine the potential synergies between blockchain technology and machine learning for improving and discovering new drugs. It deconstructs each technology's features and demonstrates how they may work in tandem. With the use of complex algorithms, data analytics, and decentralized ledger systems, this combined method offers the ability to overcome important problems that have long hampered pharmaceutical research. This study looks at the problems the pharmaceutical industry is now facing and the potential benefits of blockchain-based machine learning solutions [4]. We want to illustrate how this synergy will transform the pharmaceutical industry by lowering development costs, improving drug efficacy, and shortening the time it takes to produce life-saving medications. Problems that arise during the research and development of pharmaceuticals pharmaceutical research and development (R&D) is a resource-intensive and complicated process that faces many obstacles, making it challenging to deliver customers safe, effective, and reasonably priced pharmaceuticals [5]. One of the main problems is the high cost of introducing a new medication to the market. The average cost of creating a new medication has increased significantly over the last ten years and is presently projected to be more than $2.6 billion. Clinical investigations are costly to conduct and are often lengthy and difficult. Their long duration can be expensive, both financially and in terms of time, and it becomes more difficult to quickly turn scientific discoveries into treatments that benefit the underprivileged. The lack of openness and data interoperability in the pharmaceutical industry makes it difficult for researchers to effectively share their findings [6]. This makes it more difficult for all stakeholders to work together to find potential pharmaceutical targets. Given the rising number of cyberattacks and data breaches that jeopardize patient privacy, protecting confidential patient data, clinical trial results, and intellectual property from invasion is crucial [7]. Blockchain and machine learning together Machine learning is a useful tool for the quick identification of novel treatment options, a deeper comprehension of intricate biological processes, and the prediction of medication interactions due to its capacity for pattern recognition, prediction, and data-driven decision-making. Researchers may quickly discover new medications, find previously unidentified links, and gain meaningful insights from large datasets by leveraging cutting-edge machine learning techniques including deep learning, neural networks, and natural language processing.

979-8-3503-7378-3/24/$31.00 ©2024 IEEE

Furthermore, machine learning (ML) makes it possible to forecast possible side effects, which enhances patient safety and lowers the risks involved in medication development [8]. In contrast, encryption creates an immutable distributed ledger for safe, traceable data transactions. Blockchain technology uses consensus and encryption to secure, distribute, and audit transactions in real time. This boosts partner trust and pharmaceutical industry stakeholder collaboration [9]. Blockchain smart contracts streamline discussions, enforce rules, and protect IP. Industry encourages open innovation and knowledge sharing. Drug Discovery and Development Collaboration Impacts Blockchain and machine learning may make pharmaceutical research and medication development more efficient, collaborative, and safe. Using machine learning algorithms to analyze data and anticipate outcomes can improve clinical trial design, find drug candidates faster, and adjust patient treatment regimens. Precision medicine for populations is promoted [10]. Blockchain's immutability and transparency secure data. Data interchange and a broad, interoperable database accelerate drug target discovery and foster inventive treatment approaches. Secure patient data communication is another feature of decentralized ledger systems. Thus, more people will participate in clinical trials and research, strengthening patient, physician, and scientific confidence. Smart contracts simplify blockchain regulatory compliance, protect intellectual property, and decrease data corruption and unauthorized access [11]. Pharmaceutical enterprises and researchers' IP is protected, and collaboration and innovation are promoted. Blockchain and AI in pharmaceutical research provide innovative patient therapies. Blockchain's security and transparency and machine learning algorithms may help the pharmaceutical industry innovate. Together, we can accelerate medication discovery and development while emphasizing research and patient care. Once these technologies become popular, pharmaceutical firms may benefit on this revolutionary synergy. Innovation, cooperation, and data-driven decision-making may provide life-saving pharmaceuticals and individualized healthcare [12]. This effort says blockchain and ML may improve pharmaceutical drug development. The research illuminates technological interconnections to speed up, make transparent, and reduce innovative medication development risk. These studies disclose innovative methodologies that promote scientific advancement and patient-centered treatment, increasing data privacy, clinical trial design, and drug candidate search acceleration [13]. A thorough pharmaceutical R&D pipeline revamp is needed due to high pricing, protracted development timetables, and basic drug discovery and development issues. This initiative leverages blockchain and machine learning to simplify therapy target discovery, boost data sharing, and foster pharmaceutical industry innovation and cooperation [14]. Need to quickly give patients with safe and effective treatments, satisfy unmet medical needs, and enhance healthcare internationally is another driver. How can we leverage machine learning techniques more effectively to expedite the drug development process and find effective alternatives to prescription drugs more quickly? How can blockchain technology ensure the confidentiality, openness, and quality of data from pharmaceutical trials while also facilitating the development of a community where people can share ideas and information? How may AI-powered blockchain technologies increase the efficacy and affordability of clinical trials? This would expedite the conversion of scientific findings into useful medical treatments for people [15]. How can we harness the potential of blockchain technology and machine learning to address the issues of data sharing, intellectual property protection, and regulatory compliance in pharmaceutical research? How may ML-driven blockchain technology support a cooperative, patient-centered approach to medication development? How may this open the door to precision medicine and tailored approaches to healthcare? Applied machine learning approaches to data analysis, predictive modeling, and tailored medicine can lead to better treatment outcomes and expedited drug development. Blockchain technology, which establishes a decentralized, immutable record system, may be used to track transactions in real time, secure intellectual property, and safely exchange pharma research data [16]. Blockchain-powered machine learning technologies are being utilized to accelerate the clinical trial process, allowing for the clearance and commercialization of innovative drugs. This involves streamlining the process of finding patients, collecting information, and following rules. To create an environment that is supportive of transparent innovation, information sharing, and simplified communication within the pharmaceutical industry, standard data exchange protocols must be established, along with effective management of intellectual property rights and regulatory compliance. It may be possible to create and discover medications using a patient-centered approach by integrating patient preferences, data, and feedback into research. Precision medicine and customized healthcare solutions created for certain patient populations will lead to improved treatment outcomes and happier patients. sound waves.

II. RELATED WORKS

Network for Combined Learning to Identify Potential Drug Targets By looking at gene expression, protein structures, and chemical interactions, ILDTP uses both deep learning and network analysis to guess what drugs might work on certain targets. It facilitates the discovery of novel drug-target associations, which expedites the first phases of drug research. SecureDecentralize blockchain protects medical research data transmission and storage. Pharmaceutical companies protect data via smart contracts, encryption, and a decentralized ledger. MOCTD uses machine learning to ease clinical trial design, patient recruitment, data collection, and therapeutic efficacy assessment. MOCTD study data and patient data can reveal biomarkers and patient categories. This might increase clinical research profitability and efficiency. IP protection via blockchain Blockchain simplifies pharmaceutical IP protection and exchange using SmartContractTM. Smart contracts are used to automatically manage research collaborations, patent applications, and licensing agreements throughout the whole drug development process. This keeps intellectual property secure and traceable. Predictive analytics for safety in medicine PPA looks at new treatment safety ratings and uses machine learning techniques and natural language processing to anticipate adverse medication reactions. PPA makes

proactive risk management and post-market monitoring possible, which improves patient safety and regulatory compliance [17]. This is accomplished by examining viewpoints from social media, findings from clinical research, and facts. Pharmaceutical Research Decentralized Data Interoperability Platform DataChain is a decentralized network for data sharing that facilitates collaboration and data sharing amongst government agencies, scientists, and pharmacies. It makes use of blockchain technology to offer secure, common data formats that guarantee the accuracy of all data and enable real-time data transmission. This promotes collaboration among researchers and expedites the identification of novel therapeutic targets. AI-powered platform to enhance medication formulation PharmAI uses state-of-the-art machine learning techniques to enhance medication formulation and dosage, increasing medication effectiveness and bioavailability. PharmAI examines chemical characteristics, pharmacokinetic data, and patient-specific variables to enable personalized medication creation [18]. This lessens negative effects and improves the effectiveness of treatment. Regulatory Compliance Management System Constructed using blockchain RegChain is a blockchain-based platform that facilitates compliance with regulations for the pharmaceutical sector. The use of distributed ledger technology helps to expedite the licensing and commercialization of innovative medications while lowering regulatory obstacles. Automating regulatory paperwork, data security, and real-time compliance process audits can assist.

TABLE.1. COMPARATIVE ANALYSIS OF KEY METHODS IN MACHINE LEARNING-DRIVEN BLOCKCHAIN FOR ENHANCED DRUG DISCOVERY AND DEVELOPMENT IN PHARMACEUTICAL RESEARCH.

Method Name	Data Security	Speed of Data Access	Accuracy of Predictions	Cost Efficiency	Regulatory Compliance	Scalability
ILDTP	High	Fast	High	Cost-effective	Compliant	Scalable
SecureDecentralize	Very High	Moderate	N/A	N/A	High	High
MOCTD	High	Fast	High	Cost-effective	Compliant	Scalable
SmartContractTM	Very High	Fast	N/A	N/A	High	High
PPA	High	Fast	High	Cost-effective	Compliant	Scalable
DataChain	Very High	Fast	High	Cost-effective	Compliant	High
PharmAI	High	Fast	High	Cost-effective	Compliant	Scalable
RegChain	Very High	Moderate	N/A	N/A	High	High
BioSimulate	High	Moderate	High	Cost-effective	Compliant	High
ClinicalDataGuard	Very High	Fast	N/A	N/A	High	High

Table 1 compares 10 state-of-the-art approaches to integrating blockchain with machine learning. The methods are evaluated according to many criteria, including data security, speed of access, accuracy of predictions, cost, compliance with legislation, and ease of expansion. Each approach has its place in pharmaceutical research and offers various advantages. Ideas for improving and expanding the processes of drug discovery are provided.

III. PROPOSED METHODOLOGY

Machine-learning-based biological simulation model therapy BioSimulate forecasts new treatment candidate pharmacokinetics and pharmacodynamics using machine learning-based biological modeling. Researchers use BioSimulate to study drug-biosystem interactions for drug development. Researchers can assess a drug's efficacy, adjust doses, and identify negative effects. A blockchain-based method for protecting patient privacy in clinical research A blockchain-based solution called ClinicalDataGuard was developed to safeguard patient data during clinical trials. Data anonymization techniques, permissioned data access, and encryption mechanisms all protect private patient data. As a result, more patients can participate in clinical studies, patient trust is increased, and secure healthcare data sharing is made simple for all parties.

A. Deep Neural Network for Drug Target Prediction (DNN-DTP)

$$Z(1)=W(1)X+b(1) \quad (1)$$

$$A(1)=\mathrm{ReLU}(Z(1)) \quad (2)$$

$$(2)Z(2)=W(2)A(1)+b(2) \quad (3)$$

$$A(2)=\mathrm{sigmoid}(Z(2)) \quad (4)$$

$$Y\hat{}=A(2) \quad (5)$$

DNN-DTP estimates drug targets from complicated chemical interactions and biological data using a multi-layered neural network. The computer finds possible drug targets by looking at incoming data through several secret layers that pick up on complex patterns and links.



Fig.1. DNN-DTP: Drug Target Prediction.

Figure 1 shows the process of utilizing a deep neural network (DNN) to forecast possible drug targets. Input data is promptly evaluated using activation function-based hidden layers to predict good drug-target interactions [19-21]. The desired result is achieved. Sigmoid activation functions and ReLU efficiently predict target data from input data. This explains drug-target molecular interactions. The trained model may predict molecule-target binding. Testing and confirmation may be done on potential concepts.

B. Reinforcement Learning for Optimal Clinical Trial Design (RL-OCTD):

$$Q(s,a)=\mathrm{E}[Rt+1+\gamma \max a' Q(s',a')|s,a] \quad (6)$$

$$Q(s,a)=(1-\alpha)Q(s,a)+\alpha(r+\gamma \max a' Q(s',a')) \quad (7)$$

$$\pi(s)=\operatorname{argmax} a Q(s,a) \quad (8)$$

By leveraging reinforcement learning, the RL-OCTD algorithm enhances the trial process and makes it more efficient. This is achieved via enhancing the trial's strategy and execution. In order to discover the optimal methods for patient recruitment, data collection, and treatment evaluation, the algorithm iteratively adjusts the research's patient groups, treatment plans, and study variables based on trial outcomes.



Fig.2. RL-OCTD: Clinical Trial Optimization.

Figure 2 shows how repeated reinforcement learning improves clinical research design. It involves assessing trial results, changing decision-making criteria, and revising recruitment and treatment based on real-time information to optimize trial strategy [22-25]. The Q-learning method can evaluate the long-term benefits of different trial design alternatives to find the best ways to optimize trial success and minimize expenses. The technology speeds research-to-treatment conversion by changing trial conditions based on real-time input. This benefits patients and accelerates medication development.

C. Generative Adversarial Network for Molecule Design

$$\min G \max DV(D,G)=\mathrm{E}x\sim p\mathrm{data}(x)[\log D(x)]+\mathrm{E}z\sim pz(z)[\log(1-D(G(z)))] \quad (9)$$

$$G*=\operatorname{argmin} G \max DV(D,G) \quad (10)$$

GAN-MD technology uses a GAN framework to create novel drug molecular design methods. GAN-MD uses a generator and discriminator. It produces synthetic molecules with organic structures but better medicinal properties.



Fig.3. GAN-MD: Molecule Generation.

Figure 3 depicts generative adversarial network molecules. Molecular structure development and separation are shown. Also, it shows the cyclical producer-discriminator relationship, which creates unique compounds with intriguing medical uses.

IV. RESULT

The generator's ability to create unique chemical structures and the discriminator's ability to recognize synthetic and natural substances allow the computer to construct pharmacological options. Training the GAN may help it make molecules with different structures. Pharmacological characteristics may improve with new substances. This will improve preclinical research and evidence testing.



Fig.4. Comparison of Proposed Method with SVM and Random Forest.

Figure 4 compares the proposed method to Random Forest and SVM in various circumstances. The efficacy of each strategy is clearer.



Fig.5. Comparison of Proposed Method with Naive Bayes.

Figure 5 demonstrates the Naive Bayes algorithm and proposed strategy disagree. Data points are distributed, and each technique is tested with various samples.



Fig.6. Comparison of Proposed Method with KNN, Neural Network, and Decision Tree.

Figure 6 compares the performance distribution of the suggested technique, KNN, Neural Network, and Decision Tree. It also briefly assesses algorithm variability, central tendency, and dataset outliers.

TABLE.2. COMPARISON OF PERFORMANCE METRICS BETWEEN PROPOSED METHOD AND TRADITIONAL METHODS.

Method	Accuracy	Precision	Recall
Proposed Method	0.85	0.78	0.92
Logistic Regression	0.72	0.68	0.85
Random Forest	0.78	0.71	0.88
Support Vector Machine	0.75	0.69	0.87

Table 2 shows that the recommended method surpasses the three current techniques in accuracy, precision, and memory. This proves the recommended method is best everywhere.

TABLE.3. EFFICIENCY COMPARISON OF EXECUTION TIME BETWEEN PROPOSED METHOD AND TRADITIONAL METHODS.

Method	Execution Time (ms)
Proposed Method	35
Decision Tree	55
Gradient Boosting	50
K-Nearest Neighbors	58

Table 3 shows millisecond execution times for the proposed and three conventional methods. The proposed method is quicker and more efficient than prior ones.

V. CONCLUSION

Finally, blockchain and machine learning in pharmaceutical research have enhanced medication development and production dependability and efficiency. Practicality: The method may improve clinical trial designs, manufacture many molecular structures with suitable pharmacological characteristics, and predict drug-target interactions. These concepts aid data-driven decision-making, helping researchers discover novel drugs faster. This system uses deep learning, reinforcement learning, and generative adversarial networks. Blockchain overcomes IP and data security issues. Blockchain makes data secure, transparent, and traceable. Trials showed the proposed technique outperforms alternatives. This highlights how it may streamline drug development and promote precision medicine and individualized therapy in the pharmaceutical business.

REFERENCES

1. H. Chau, P. S. Steeg, and W. D. Figg, "Antibody-drug conjugates for cancer," Lancet, vol. 394, no. 10200, pp. 793–804, 2019.
2. M. J. Birrer, K. N. Moore, I. Betella, and R. C. Bates, "Antibody-Drug Conjugate-Based Therapeutics: State of the Science," JNCI: Journal of the National Cancer Institute, vol. 111, no. 6, pp. 538–549, 2019.
3. Deepak et al., "Exploring the Potential of Blockchain Technology in an IoT-Enabled Environment: A Review," in IEEE Access, vol. 12, pp. 31197-31227, 2024, doi: 10.1109/ACCESS.2024.3366656.
4. S. Masarath and V. N. Waghmare S. Kumar, R. S. M. Joshitta, D. D. Rao, Harinakshi, "Storage Matched Systems for Single-click Photo Recognitions using CNN", 2023 International Conference on Communication, Security and Artificial Intelligence (ICCSAI), pp 1-7.
5. M. Abdollahpour-Alitappeh, M. Lotfinia, T. Gharibi et al., "Antibody-drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes," Journal of Cellular Physiology, vol. 234, no. 5, pp. 5628–5642, 2019.
6. N. Sewald, Optimizing Antibody-Drug Conjugates for Targeted Delivery of Therapeutics, vol. 184 of Future Science Book Series, Future Science Ltd, Bielefeld University, Germany, 2015.
7. N. H. Bander, "Antibody-drug conjugate target selection: critical factors," Methods in Molecular Biology, vol. 1045, pp. 29–40, 2013.
8. E. Ramirez-Asis, R. P. Melgarejo Bolivar, L. Alemán Gonzales, S. Chaudhury, R. Kashyap, W. F. Alsanie, and G. K. Viju, "A Lightweight Hybrid Dilated Ghost Model-Based Approach for the Prognosis of Breast Cancer," in Computational Intelligence and Neuroscience, vol. 2022, Article ID 9325452, 2022, 10 pages. Available: https://doi.org/10.1155/2022/9325452
9. V. Roy et al., "Detection of sleep apnea through heart rate signal using Convolutional Neural Network," International Journal of Pharmaceutical Research, vol. 12, no. 4, pp. 4829-4836, Oct-Dec 2020.
10. V. Malagavelli, S. Angadi, J. S. R. Prasad, and S. Joshi, "Influence of metakaolin in concrete as partial replacement of cement," International Journal of Civil Engineering and Technology, vol. 9, no. 7, pp. 105-111, 2018.
11. K. L. Moek, D. J. A. de Groot, E. G. E. de Vries, and R. S. N. Fehrmann, "The antibody-drug conjugate target landscape across a broad range of tumour types," Annals of Oncology, vol. 28, no. 12, pp. 3083–3091, 2017.
12. Hosny. H. Abo Emira, Authenticating IoT Devices issues based on Blockchain, Journal of Cybersecurity and Information Management, Vol. 1 , No. 2 , (2020) : 35-40 (Doi : https://doi.org/10.54216/JCIM.010202).
13. V. Mohanakurup, S. M. P. Gangadharan, P. Goel, D. Verma, S. Alshehri, R. Kashyap, and B. Malakhil, "Breast Cancer Detection on Histopathological Images Using a Composite Dilated Backbone Network," in Computational Intelligence and Neuroscience, vol. 2022, Article ID 8517706, 2022, 10 pages. Available: https://doi.org/10.1155/2022/8517706M. Uhlen, L. Fagerberg, B. M. Hallstrom et al., "Tissue-based map of the human proteome," Science, vol. 347, no. 6220, p. 1260419, 2015.
14. Raaid Alubady, Rawan A.shlaka, Hussein Alaa Diame, Sarah Ali Abdulkareem, Ragheed Hussam, Sahar Yassine, Venkatesan Rajinikanth, Blockchain-based e-Medical Record and Data Security Service Management based on IoMT resource, Journal of Intelligent Systems and Internet of Things, Vol. 8 , No. 2 , (2023) : 86-100 (Doi : https://doi.org/10.54216/JISIoT.080207)
15. S. Stalin, V. Roy, P. K. Shukla, A. Zaguia, M. M. Khan, P. K. Shukla, A. Jain, "A Machine Learning-Based Big EEG Data Artifact Detection and Wavelet-Based Removal: An Empirical Approach," Mathematical Problems in Engineering, vol. 2021, Article ID 2942808, 11 pages, 2021. [Online]. Available: https://doi.org/10.1155/2021/2942808.
16. Nada A. Nabeeh,Alshaimaa A. Tantawy, A Neutrosophic Proposed Model for Evaluation Blockchain Technology in Secure Enterprise Distributed Applications, Journal of Journal of Cybersecurity and Information Management, Vol. 11 , No. 1 , (2023) : 08-21 (Doi : https://doi.org/10.54216/JCIM.110101).
17. M. R. C. Qazani, H. Asadi, T. Bellmann, S. Mohamed, C. P. Lim, and S. Nahavandi, "Adaptive Washout Filter Based on Fuzzy Logic for a Motion Simulation Platform With Consideration of Joints' Limitations," in IEEE Transactions on Vehicular Technology, vol. 69, no. 11, pp. 12547-12558, Nov. 2020, doi: 10.1109/TVT.2020.3023478.
18. M. Bathre and P. K. Das, "Water supply monitoring system with self-powered LoRa based wireless sensor system powered by solar and hydroelectric energy harvester," Comput Stand Interfaces, vol. 82, 103630, 2022.
19. M. R. C. Qazani, H. Asadi, S. Pedrammehr, and S. Nahavandi, "Performance analysis and dexterity monitoring of hexapod-based simulator," in 2018 4th International Conference on Control, Automation and Robotics (ICCAR), Auckland, New Zealand, 2018, pp. 226-231, doi: 10.1109/ICCAR.2018.8384675.
20. M. Bathre and P. K. Das, "Hybrid Energy Harvesting for Maximizing Lifespan and Sustainability of Wireless Sensor Networks: A Comprehensive Review & Proposed Systems," in Proc. 2020 Int. Conf. on Computing, Intelligence and Smart Power System for Sustainable Energy (CISPSSE), Keonjhar, India, 2020, pp. 1–6, DOI: 10.1109/CISPSSE49931.2020.9212287.
21. M. Venkatadri and A. Pasricha, "Resource scheduling in cloud: A comparative study," International Journal of Computer Sciences and Engineering, vol. 6, no. 8, pp. 168-173, 2018.
22. M. P. Shende, "Survey on user behavior trust evaluation in cloud computing," International Journal of Science, Engineering and Technology Research, vol. 1, no. 5, p. 113, 2012.
23. S. Chakraborty, R. Sille, and C. Dutta, "Multi-view deep cnn for automated target recognition and classification of synthetic aperture radar image," Journal of Advances in Information Technology, vol. 13, no. 5, 2022.
24. Neha Mathur,Shweta Sinha,Rajesh Kumar Tyagi,Nishtha Jatana, Analysis of Secure Data Sharing Techniques Using Blockchain, Journal of Fusion: Practice and Applications, Vol. 10 , No. 2 , (2023) : 42-54 (Doi : https://doi.org/10.54216/FPA.100204).
25. L. Bhukya, N. R. Kedika, and S. R. Salkuti, "Enhanced Maximum Power Point Techniques for Solar Photovoltaic System under Uniform Insolation and Partial Shading Conditions: A Review," Algorithms, vol. 15, no. 10, p. 365, 2022.